RedHill Biopharma: Net revenues for Q1-18 are lower than estimated; RedHill will have to raise capital in anticipation of its announcement of top-line Phase III results for Crohn’s disease, expected in mid-2018; target price remains at NIS 2.59

• jaimeuss_admin
• 16 בSeptember 2018
• Research
• 0 Comments

Continue Reading

Energix: Entering the US market is a significant long-term growth opportunity; major project and regulatory milestones in Poland and Israel increase installed capacity; new in-house O&M and project management capabilities improve financial and operational efficiency; target price raised to NIS 4.05.

• jaimeuss_admin
• 6 בSeptember 2018
• Research
• 0 Comments

Continue Reading

Cellect. On track with its strategic plans; successfully completed proof of concept for ApoTainerTM; sufficient cash to support clinical and preclinical trials; price target unchanged

• jaimeuss_admin
• 30 בAugust 2018
• Research
• 0 Comments

Continue Reading